Innovative anemia therapy: Development of new anemia drugs targeting the novel mechanism of erythropoiesis
update：2020-06-16
Anemia is a very prevalent disease. Nevertheless, an effective therapy is yet to be discovered. Erythropoietin is effective only for those with renal dysfunction. We have found that inhibition of an enzyme for epigenetic regulation results in a prominent increase of erythropoiesis, pointing to a new target for anemia therapy. We have also generated a new, cell-based assay system for the enzymatic activity and carried out small molecule screening.
Collaboration with industry partners
We are seeking a collaboration to accelerate the development of new anemia drugs based on these findings. Together we will advance the development of the candidate molecules currently identified as well as conduct further screening of larger chemical space for better candidates and/or for drug repositioning.
Researchers
Department of Biochemistry, Tohoku University Graduate School of Medicine
IGARASHI Kazuhiko
, Professor
Doctor of Medicine
Keywords
Related Information
https://www.nature.com/articles/s41590-018-0202-3
Prev
List
Next